Feature | July 09, 2013

New Correlation for Increased Mortality Associated with Transcatheter Valve Replacement

July 9, 2013 — Researchers have announced the results of a clinical study that shows a key difference in the patient’s baseline heart size and function following transcatheter valve replacement (TAVR) that may help predict their medical outcomes. Previous work by these researchers showed that even mild paravalvular aortic regurgitation (PAR), detected by echocardiograms performed on these patients, appears to correlate with increased mortality. The current study revealed that certain baseline characteristics found on the echocardiograms could help predict which patients were more likely to have PAR.

“This is an exciting discovery that will help us better stratify patients for closer follow-up care,” said Rebecca Hahn, M.D., FASE, the study’s primary investigator. Hahn and her colleagues analyzed 465 patients from the PARTNER trial, combined with another 1,757 patients to show the association between increased PAR and the significant difference in baseline echo parameters. The patients’ echocardiograms indicated larger ventricular volumes and mass, lower ejection fractions and more regurgitant valvular disease, all of which appear to be harbingers of underlying issues that influenced the patient’s long-term outcome following the procedure.

Researchers on the study, "Differences in Baseline Echo Parameters in Patients with Varying Severity of Paravalvular Regurgitation Following Transcatheter Valve Replacement," included Rebecca Hahn, Susheel Kodali, Mathew Williams, Tom McAndrew and Martin Leon from Columbia University, New York, N.Y.; Pamela S. Douglas from Duke University Medical Center, Durham, N.C.;  Philippe Pibarot from Laval University, Quebec, QC, Canada; William Stewart from the Cleveland Clinic Foundation, Cleveland, Ohio; and Neil Weissman from Medstar Health Research Institute, Washington, D.C.

For more information: www.asecho.org

Related Content

HeartFlow, FFR-CT, ruptured coronary plaques, EMERALD study, EuroPCR 2016
News | CT Angiography (CTA)| May 23, 2016
First-in-human data presented at EuroPCR 2016 demonstrate that hemodynamic data from HeartFlow Inc. may help predict...
Mitralign, Series E funding, Trialign, MPAS
News | Heart Valve Technology| May 23, 2016
Mitralign Inc. announced it has raised $39.8 million to date in a Series E equity round of financing.
TAVR outcomes, aortic valve gradient, JACC study
News | Heart Valve Technology| May 23, 2016
Patients with a combination of left ventricular dysfunction and low aortic valve gradient have higher mortality rates...
Direct Flow Medical, TAVR device, DISCOVER trial, three-year results, EuroPCR 2016
News | Heart Valve Technology| May 20, 2016
Direct Flow Medical Inc. presented three-year results from its prospective, multicenter DISCOVER Trial at the EuroPCR...
Bioventrix, Revivent-TC System, heart failure, first-in-man procedure
News | Heart Failure| May 19, 2016
BioVentrix announced the first-in-man use of its next-generation Revivent-TC System with an endovascular catheter-based...
St. Jude Medical, EuroPCR 2016 studies, FFR, LAAO, left atrial appendage occlusion, fractional flow reserve, Amplatzer
News | Cath Lab| May 19, 2016
St. Jude Medical Inc. announced results from two cardiovascular clinical trials presented at EuroPCR 2016.
bioabsorbable vascular graft, children, feasibility study, Bakoulev Center Moscow, AATS 2016 meeting

Image courtesy of Bakoulev Scientific Center for Cardiovascular Surgery

News | Stent Grafts| May 18, 2016
Bioabsorbable heart valves or blood vessels are designed to harness the body’s innate healing process, enabling the...
RDAVR, aortic valve replacement, Edwards Intuity, TRANSFORM Trial, AATS meeting
News | Heart Valve Technology| May 18, 2016
The TRANSFORM trial was designed to evaluate the safety and performance of an investigational rapid deployment aortic...
Technology | Cardiac Imaging| May 18, 2016
May 18, 2016 — The Intersocietal Accreditation Commission (IAC) recently announced its launch of the IAC QI Self-Asse
NeoChord, DS1000 System, FDA approval, U.S. pivotal trial
News | Heart Valve Technology| May 17, 2016
NeoChord Inc. announced it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug...
Overlay Init